

An Anti-Counterfeiting Strategy Using Numeric Tokens

Roger G. Johnston, Ph.D., CPP*
Vulnerability Assessment Team
Los Alamos National Laboratory
MS J565, Los Alamos, NM 87545 USA
phone: 505-667-7414, fax: 505-665-4631
email: rogerj@lanl.gov

* Head of the Vulnerability Assessment Team at Los Alamos National Laboratory.

Abstract:

The counterfeiting of pharmaceuticals continues to be a major worldwide problem, with serious public health and economic consequences. In theory, anti-counterfeiting tags could help to solve this problem. Unfortunately, there are currently no practical, effective tags that significantly resist counterfeiting. This paper discusses a different, relatively low-tech and low-cost approach called the “Call-in the Numeric Token” (CNT) technique. It relies on participation by pharmaceutical customers (possibly including consumers). They check, via phone or Internet, on the validity of the unique, random, unpredictable identity (ID) number assigned to each pharmaceutical container they possess. The numerical container ID is a virtual tag or token, rather than a physical one that is susceptible to counterfeiting. Counterfeiters are hampered by being unable to guess valid IDs, by being unable to easily acquire large numbers of existing valid IDs, and by being detected when multiple customers report the same IDs. At least some counterfeits can be detected even if only a small percentage of customers participate. The technique is particularly well suited for single-dose (“unit of use”) packaging, but can otherwise be adapted and automated for resellers, wholesalers, repackagers, and other high-volume customers. While it will not absolutely end counterfeiting, CNT can make pharmaceutical counterfeiting easier to detect and study, and more difficult for counterfeiters. The technique is also applicable to other kinds of products.

Introduction

Counterfeit pharmaceuticals continue to be a major problem, with serious medical and economic consequences.^[1-6] In theory, high-tech tags placed on packaging, or taggants doped into the product, could be used to authenticate pharmaceuticals and other medical products. (A “tag” is a device or feature that uniquely identifies an object or container. A “taggant” is a trace chemical added to a product to give it a unique “fingerprint”.)

To be practical, tags or taggants need to be (1) inexpensive, (2) difficult and/or expensive to counterfeit, and (3) quick and easy for non-technical personnel to verify. In practice, such tags or taggants do not currently exist.^[7-10] They may not even be possible.^[7-9] Indeed, according to the FDA, “All anti-counterfeiting technologies can be defeated.”^[6] This statement is certainly consistent with our experiences in the Vulnerability Assessment Team (VAT) at Los Alamos National Laboratory.^[11-13]

Inventors, manufacturers, and vendors of anti-counterfeiting tags often claim to have a unique manufacturing process that nobody else can duplicate. In our experience in the VAT, this is usually untrue. Moreover, one factor often overlooked in discussions about anti-counterfeiting tags is the fact that a tag (and its real performance) does not actually need to be counterfeited for an adversary to be successful. Instead, only the superficial appearance and apparent performance of the tag usually needs to be mimicked. This is much easier and cheaper.

Clandestine taggants, or covert tags such as secret inks^[14] and surreptitious packaging marks^[6,10,14-16] appear to be particularly impractical, especially for use by individual consumers. Moreover, they require keeping secrets—not a viable long-term security strategy for consumer products. Besides, the trace contaminants in pharmaceuticals already serve as a unique, hard to counterfeit “fingerprint” that can be analyzed in a laboratory, though at great cost.

Passive radio frequency transponders (RFIDs) or memory contact buttons are another common suggestion for anti-counterfeiting tags^[6,14-16], but we in the VAT have demonstrated that they can be cheaply and easily counterfeited.^[11,12,17, 18]

This paper discusses an alternative anti-counterfeiting technique that does not require high-tech or covert tags or taggants. While imperfect, it nevertheless offers the possibility of at least partially detecting counterfeits and impeding counterfeiters at relatively modest cost. This strategy, termed the “Call-In the Numeric Token”

(CNT) technique, would also be applicable as an anti-counterfeiting strategy for other kinds of products, both medical and non-medical.

The case for this new approach will be presented as follows: The basic concept and elements of the CNT technique are discussed first, followed by implementation issues. Statistics for the technique are briefly covered; these show that the technique can theoretically be fairly proficient at identifying counterfeits. Problems and attack strategies are analyzed next, along with intrinsic CNT attributes and possible countermeasures that can serve as mitigating factors. The next section explains how the CNT technique differs from FDA anti-counterfeiting proposals. The final section before the Conclusion offers other comments about the CNT technique.

The Proposed CNT technique

The “Call-In the Numeric Token” (CNT) Technique has 4 required components. These are: (1) a unique container identification number or “Bottle ID”, (2) a secret computer database of Bottle IDs maintained by the pharmaceutical manufacturer, (3) a dedicated web page and/or automated phone line(s) for customers to “call in” to check their Bottle ID(s), and (4) some degree of customer participation (even if far from universal). “Customer” here can mean individual consumers, but also wholesalers, repackagers, pharmacies, hospitals, and other companies and institutions that handle large volumes of pharmaceuticals.

Currently, most pharmaceutical containers or packaging are marked with the appropriate Lot Number and Expiration Date. The CNT technique requires that an additional identification (ID) number be applied. For simplicity of discussion, this ID number will be referred to as the “**Bottle ID**”, even though the ID number might instead be applied to the packaging, or even to a different type of drug container such as a tube, box, drum, pallet, or even a truck, depending on the application.

The “Bottle” ID can be inserted into, or printed on, the container (or packaging) during manufacture, or else added at a later date by applying an adhesive label. The Bottle ID doesn’t even have to be physically attached to the pharmaceutical container at all.

In randomly choosing a Bottle ID for each “bottle” (perhaps at the very instant of printing), a computer must obey the following rules:

Rule 1: The Bottle ID must be a unique number (no duplication) for each bottle within a given Lot. Thus, two bottles can have the same Bottle ID only if they come from a different manufacturing Lot.

Rule 2: The ID is not a serial number; it must be random, non-sequential, and unpredictable.

Rule 3: There must be at least 1000 times more possible Bottle IDs than actual bottles produced for a given Lot.

Figure 1 shows an example of the markings on a bottle under the CNT scheme. The Bottle ID format in this example (3 letters followed by 3 numeric digits) allows about 17.6 million unique ID numbers, and thus up to 17,576 different bottles (under Rule 3 above) for this Lot. See Table 1. It is not actually necessary to use a consistent format for the Bottle ID numbers, either within a given Lot or between Lots. Variability can further frustrate the counterfeiters' task of determining valid ID numbers.

A computer needs to keep track of the actual Bottle IDs printed for a given Lot. Only those Bottle IDs are authorized or "**valid**"; a non-valid Bottle ID indicates a counterfeit product. The database of valid Bottle IDs needs to be kept secret by the pharmaceutical manufacturer, at least until the appropriate Lots expire.

Note that keeping track of the valid Bottle IDs via computer requires only modest storage. For example, a maximum of 53 kBytes are needed per Lot for the (3 letter + 3 digit) Bottle ID format shown in figure 1. (~3 bytes x 17,576 bottles.) Thus, a single CD or DVD could hold data for 250 million and 1500 million bottles, respectively. Data compression would permit an even greater capacity.

The pharmaceutical manufacturer, the government, or an association of manufacturers, would need to establish a public Internet site and/or dedicated phone line. Ideally, the phone line is automated with voice recognition software to simplify its use for consumers. The web site and/or phone line allows customers to quickly check whether their Bottle IDs are valid for the appropriate Lot Number(s). (This is termed "**calling in**".) Customers are only given a yes/no response, i.e., they are told only that the bottle appears to be authentic or not. If the latter, they would be encouraged to return the counterfeit drugs to the manufacturer for analysis, and to obtain a replacement.

Regardless of the number of other customers who "call in", a customer's invalid Bottle ID(s) can be immediately identified by the web site or phone line with

essentially 100% accuracy when she calls in. An invalid Bottle ID (unless the customer made an error or is not being sincere) is a sure indication that the drug is counterfeit.

Even without calling in, high-volume customers can spot some counterfeits by simply noting duplicate Bottle IDs within their own (current and previous) stock. To be practical, this “**self-check**” would require automated reading and data logging of the Bottle IDs. Because counterfeits tend to cluster in time and space, self-checking can be a powerful method for detecting counterfeits.

If multiple customers call in identical, valid Bottle IDs, this indicates that most or all of their pharmaceuticals are counterfeits. It tells us that the counterfeiters are replicating at least some valid Bottle IDs to assist in their drug counterfeiting. See below for a discussion of how counterfeiters can obtain valid Bottle IDs, and why it is challenging to obtain large numbers of them.

If only a few Bottle IDs are found to have been replicated in large numbers by counterfeiters, pharmaceutical manufacturers could issue public warnings about those specific Bottle IDs. The FDA’s MedWatch system^[6] would be one mechanism. This might alert even customers who don’t call into the CNT system.

Implementation

It may be advantageous to bar-code the Lot Number and Bottle ID on the bottle or packaging, or encoded them in a radio frequency transducer (RFID) or memory contact button, or read them using computer character recognition. This would make it possible to automate the “calling-in” and “self-check” processes for wholesalers, repackagers, pharmacies, hospitals, institutions, and others who possess large quantities of drugs.

There are a number of other ways to record the Bottle ID in or on the pharmaceutical product. The Bottle ID can, for example, be placed inside the tamper-evident packaging; it can also be written on scratch-off labels such as used for lotteries. This complicates the task of a counterfeiter who may want to gain access to large numbers of valid Bottle IDs without actually purchasing the pharmaceuticals. Of course, while placing the Bottle ID inside the tamper-evident packaging may be practical for individual consumers or repackagers, it creates difficulties for wholesalers who may not want to open large numbers of containers to

determine Bottle IDs. On the other hand, we may want to vary the CNT approach for different customers and container types/sizes.

The Bottle ID might also be printed on a tear-off tab or removable adhesive label. That would reduce the chances of a given bottle being inadvertently called in twice by the same owner. (See Scenario 7 below.) A magnetic stripe that is erased in the process of being read can accomplish the same thing, as can a frangible film, with the Bottle ID printed on it that is destroyed when the consumer attempts to withdraw the first pill. The obvious disadvantage to these one-shot approaches is that a bottle cannot be easily checked by the new owner if it is resold.

It is important to note that the Bottle ID is a kind of “virtual” tag or token. It is not actually necessary for the Bottle ID to be physically inside or attached to the packaging, or even shipped at the same time as the drugs. This has important implications for repackagers and pharmacies. (See Scenario 9 below.) The Bottle IDs can be mailed or emailed to a customer at a later date. The Bottle ID in this situation is thus truly a “buddy” tag or token, not a physical tag. Each valid Bottle ID (and associated Lot Number) is, in effect, a kind of authorization to own 1 bottle. If the bottles are resold, the purchaser must insist on receiving an equal number of valid Bottle IDs. He should call in each of the Bottle IDs to see if they are indeed valid.

For licensed wholesalers or other authorized high-volume customers, it might be prudent to provide free software and readers. These would allow them to easily record Bottle IDs, self-check their stock locally for Bottle ID duplicates, and automatically call-in so they can be alerted to other counterfeits. The software would also help prevent the customer from inadvertently calling in a given bottle twice, thus improving the accuracy of the CNT results. If the reader and software record the Bottle IDs in an encrypted form (especially using a public/private key cipher^[19]), it would be more challenging for an adversary to steal the recorded valid Bottle IDs.

Statistics

As discussed above, anyone who calls in with an invalid Bottle ID (assuming he did not make a mistake and that he is not deliberately trying to spoof the CNT system) will be told correctly 100% of the time that he has counterfeit drugs. This is true regardless of the number of previous or subsequent callers.

Now consider the situation where there exists in the world 1 legitimate bottle, and N counterfeit bottles, all printed with the same valid Bottle ID. The probability that any one of these bottles will be correctly identified as counterfeit when called in is $N/(N+1)$. (This assumes that at least 2 of these bottles are called in, permitting the counterfeiting to be detected in the first place.) Table 1 shows that the CNT error rate is very low in identifying counterfeits when the counterfeiters make even a relatively small number of counterfeit bottles with the same valid Bottle ID.

For reasons discussed below, we may instead want to use a threshold greater than 2 callers before deciding that counterfeiting of a given Bottle ID has occurred. In general, when the number of callers (calling in the same Bottle ID) reaches some threshold value, T , we will report counterfeiting to that caller and all subsequent callers. Let C be the ultimate, final total number of callers reporting the same valid Bottle ID. Assuming we do not try to re-contact previous callers who made an inquiry prior to the threshold T being achieved, the percentage of total callers who will be told they hold counterfeits is equal to $100\% \times (C-T+1)/C$. This is plotted in figure 2 for four different thresholds, T .

The key point in figure 2 is that even with a high threshold (e.g. $T=10$), we can still correctly notify a significant portion of callers that they probably have a counterfeit. Of course, once the threshold is achieved for a given Bottle ID, we could always re-contact the $T-1$ previous callers (assuming they have offered their identity and contact information) to warn them that new information suggests they might have counterfeit drugs after all. This would make 100% of the callers reporting the same (valid) Bottle ID aware that they probably hold a counterfeit.

(Note that, prior to reaching the threshold T for a given valid Bottle ID, we might want to invite the first $T-1$ callers to call back at a later time to see if the situation has changed. We would encourage them to indicate they are checking back, so that their repeat call-in does not count towards the threshold T .)

Attacks, Problems, and Countermeasures

This section briefly outlines some of the problems with the CNT technique, and possible attack strategies for counterfeiters. Implications, mitigating circumstances, and countermeasures are also discussed.

Scenario 1 - Guessing Bottle IDs

Counterfeiters can randomly guess Bottle IDs. Their problem, however, is that the odds of guessing a valid Bottle ID (for a given Lot Number) are less than 1 in 1000 because of Rule 3 above. As a result, fewer than 0.1% of their counterfeit bottles (on average) will pass the call-in test. Even without calling in, high-volume customers may be able to spot the counterfeits by detecting replicate Bottle IDs within their own stock (“self-checking”).

Scenario 2 - Phishing for Bottle IDs

Counterfeiters can always try to phish for valid Bottle IDs by calling in trial numbers. (“Phishing” means trying to obtain private information by misrepresenting one’s identity and agenda, and asking relevant questions.) On average, however, it will take at least 1000 tries to get a valid Bottle ID. We can virtually eliminate this attack scenario if the callers are only given a Yes/No decision on their Bottle ID (and not allowed access to the whole database), and if we disallow unlimited inquiries from a single, unknown caller if he inquires about a large number of invalid Bottle IDs. Requiring some form of identification (such as a password, drug business license, prescription number, or invoice number) for callers may make sense for a number of reasons, especially for customers claiming to hold a large amount of stock.

Scenario 3 - Other Ways to Obtain Valid Bottle IDs

Another approach that drug counterfeiters can use to obtain valid Bottle IDs is to buy some of the authentic product. They might also try to quickly examine large supplies of the product (without purchasing) in order to record valid Bottle IDs. As a practical matter, it is likely to be time consuming, expensive, risky, and/or difficult to obtain large numbers of valid Bottle IDs. (This is especially the case if the Bottle IDs are placed inside the tamper-evident packaging.) They may be more inclined to make duplicate Bottle IDs from a relatively small number of valid numbers. But these can be detected by CNT call-ins.

Valid Bottle IDs can be obtained by one or more of the following methods:

- Legitimate products are purchased, the Bottle IDs extracted, and then the products are discarded. This can be expensive for the counterfeiters.
- Legitimate products are purchased, the Bottle IDs extracted, and then the products are resold. Returning the authentic product to the marketplace may increase the chances that the counterfeiter can be traced.

- Nefarious insiders gain access to the (single) secret Bottle ID database kept by the pharmaceutical manufacturer at company headquarters. Good security, however, can minimize this possibility. Furthermore, the Bottle IDs stored in the database are of no value once the Lots expire, or for future pharmaceuticals not yet manufactured or packaged.
- Nefarious insiders gain access to significant numbers of valid Bottle IDs at high-volume handlers, or while pharmaceuticals are in transit. Good security can help minimize this risk.
- Counterfeiters record valid Bottle IDs at retail stores or pharmacies. This may be difficult to do in large numbers, especially if the Bottle IDs are placed inside the tamper-evident packaging.

Scenario 4 - Denial of Service Attacks

Counterfeiters (or hackers) can try to sabotage the CNT system by Denial of Service (DoS) attacks.^[10] This involves tying up the call-in web site and phone lines with nuisance contacts. Counterfeiters do not benefit directly from such actions, but they might discredit the CNT system and impede or upset customers.

DoS attacks can be at least partially mitigated by using standard DoS countermeasures,^[10,20] by requiring callers to identify themselves, and/or by setting up private web sites and phone lines (unavailable to the public) for trusted, high-volume customers.

Scenario 5 - Spoofing the System

Counterfeiters (or hackers) could try to sabotage the CNT system by calling in valid Bottle IDs multiple times. Those Bottle IDs would then be incorrectly identified as having been counterfeited. Such spoofing is of no value unless they possess significant numbers of valid Bottle IDs—which is non-trivial as discussed previously.

This attack can be partially mitigated by raising the threshold, T , to a larger value than 2. As shown in figure 2, this only slightly reduces the efficiency of the CNT technique. Another countermeasure is to establish secret or private web pages and phone lines for use only by trusted wholesalers, pharmacies, and hospitals. Also, requiring callers to identify themselves (such as via a password) can be useful, as

can building in delays in the CNT system for individual consumers, making calling in large numbers of valid Button IDs very time consuming.

While they might discredit the CNT system and upset customers, the counterfeiters (or hackers) do not benefit directly from spoofing the CNT system in this manner. Moreover, the attacks may backfire. Creating the appearance of extra drug counterfeiting could focus more worldwide attention on the drug counterfeiting problem. This might encourage governments or pharmaceutical manufacturers to take additional anti-counterfeiting measures and increase prosecution—something not in the best long-term interests of the counterfeiters.

Scenario 6 - Fake Call-In Sites

Counterfeiters can establish fake web sites and phone numbers that incorrectly tell callers that their pharmaceuticals are authentic, even when this is not the case. The counterfeiters might print their fake Internet URL and phone number on the counterfeit bottles, or placed them inside the counterfeit packaging.

Pharmaceutical manufacturers can counter this attack by not including the URL or phone number for CNT call-ins on (or inside) the legitimate product. Instead, customers and consumers would need to be educated as to the correct URL or phone number to use. This could be accomplished by an extensive national or worldwide advertising campaign, including listings in telephone books, memorable radio and television jingles, and the use of a URL and phone number (e.g., 555-FAKE) that can be easily remembered.

Manufacturers might also want to periodically contact major customers directly to make sure they have the correct URL and phone number. Providing free inventory and call-in software to high-volume customers might help prevent the use of bogus URLs and phone numbers. Sales representatives could be used to provide physicians and pharmacies with informational handouts for their patients. These would contain the correct URL and phone number, as well as call-in instructions. It might also be prudent to continually scan the Internet to detect counterfeit call-in sites.

Scenario 7 - Innocent Redundancy by Customers

Consumers or other customers might innocently call-in the same bottle more than once. This can skew the counterfeit detection. Countermeasures to this problem include setting the threshold above 2; using tear-off, scratch-off, or frangible printing for the Bottle ID to minimize reuse; understanding the identity of the

callers; and/or providing high-volume customers with software that prevents this kind of error.

Scenario 8 - Duplicate Calls Due to Drug Resale

Pharmaceuticals are often resold by the original purchaser. (The FDA, however, has proposed that limiting the number of legal drug resales might be an effective anti-counterfeiting measure.^[6]) Drug resales could lead to duplicate CNT call-ins for the same bottle if both the original and subsequent owners call in.

There are several possible ways to deal with this issue. If the seller is a repackager, see the next Scenario. Otherwise, the threshold could be increased beyond 2. The use of tear-off tabs for the printed Bottle ID would cause the Bottle ID to be missing for the second owner—eliminating the duplication problem, but also offering no chance for the new owner to check on authenticity. The reseller could instead report to the pharmaceutical manufacturer which Bottle IDs were sold, though this requires extra work.

If both the original and new owners call-in and identify themselves, we can check to see if the sale is going in the correct direction, e.g., not from consumer to wholesaler, or consumer to consumer. Another approach would be to limit the CNT system to use only by one class of customers: licensed wholesalers only, pharmacies only, or consumers only. Then reselling would be less of an issue, though the efficiency in detecting counterfeits would decrease. Separate and unconnected CNT systems could also be run for each class of customers.

Scenario 9 - The Repackaging Problem

Unit of use (single dose) packaging, of course, would eliminate many of the problems associated with repackaging. The question of how to otherwise handle repackaging is a critical one. According to the FDA, “Repackaging destroys anti-counterfeiting technologies employed by the manufacturer.”^[6] With CNT, however, putting the Bottle ID inside tamper-evident packaging is not necessarily a problem for repackagers or pharmacies. They must typically open the packaging, anyway.

Repackagers can use the fact that the Bottle ID is a virtual tag, not necessarily a physical one. Thus, under CNT, a Bottle ID can be reused by repackaging, re-adhering, or reprinting it. If the repackager is consolidating small “bottles” into larger ones, he needs to only reuse a subset of the original Bottle IDs. He should then destroy the unused Bottle IDs; they become a vulnerability if stolen by (or sold to) counterfeiters, or if the repackager himself is a counterfeiter.

How do we handle the more common situation where a repackager or pharmacy is “sub-dividing”, i.e., creating more new “bottles” than the number of old bottles? There are several possibilities. Repackagers might be required to obtain authorization from the pharmaceutical manufacturer (or be sent new printed labels) for imprinting new Bottle IDs. Alternatively, they might be able to simply contact the manufacturer to state that some of the Bottle IDs will be re-used. The manufacturer can factor this information into the CNT call-in system and the choice of threshold.

A third and probably more practical approach is for the pharmaceutical manufacturer to automatically pack (a reasonable number of) multiple Bottle IDs—each one different—inside a single large bottle. (This could be done in the form of removable adhesive labels, though there are other possibilities.) Each new bottle created by an authorized repackager or pharmacy would then get one of these unique Bottle IDs that came with the original big container. This approach represents an extension of Rule 1 above, where we now create a unique Bottle ID for each virtual or future bottle. The Bottle IDs represent a kind of authorization to create a fixed number of new bottles. Unused Bottle IDs represent a vulnerability if made available to counterfeiters.

Fortunately, each unused Bottle ID that a repackager or pharmacy allows to fall into the hands of counterfeiters represents only one counterfeit bottle that the counterfeiters can safely make. If they replicate the diverted Bottle ID multiple times, the CNT call-in system has the possibility of detecting the counterfeits. Moreover, some traceability of the bootlegged Bottle IDs—pointing back to the guilty repackager or pharmacy—may be possible if CNT callers identify themselves.

Scenario 10 - Identity & Privacy Issues

Though not required, having callers identify themselves can greatly improve the security and effectiveness of the CNT technique. (For example, earlier callers can be re-contacted when it appears that a given Bottle ID has been counterfeited based on the call-in threshold. Also, instances of counterfeiting that are discovered may become traceable if the callers are known.) Having callers identify themselves, however, may raise privacy concerns and possibly discourage consumers from participating. Moreover, having to type in a password or identity information during the call-in will slow down what would otherwise be a very rapid yes/no response on the Internet or telephone.

Scenario 11 - The Best as the Enemy of the Good

The CNT technique is only a partial solution to product counterfeiting. It makes no *a priori* attempt to stop the counterfeiting, nor will it detect all counterfeits. Sometimes implementing partial measures to deal with hazards puts manufacturers in a risky situation in regards to liability. The way to counter this problem is to involve the government and/or make the CNT approach—even if imperfect—an industry best practice. Due diligence could then be claimed even if the counterfeiting problem is not totally eliminated.

A more specific problem is how to deal with a caller who is told his drugs are likely to be counterfeit when they really aren't. Ignoring caller error, this can occur when a valid Bottle ID is replicated by counterfeiters N times. One (but only one) customer will possess the single authentic bottle with that Bottle ID. If he calls in, we cannot distinguish his sole authentic bottle from the N fakes. If his drugs are mailed in for analysis, however, we can notify him later of the error, along with an apology and a statement that this was all in the interest of his safety and the greater good.

How Does CNT Differ from FDA and Other Pedigree Approaches?

In its 2004 report, “Combating Counterfeit Drugs”^[6] the FDA calls for “mass serialization” of pharmaceutical containers and extensive use of RFIDs for purposes of tracking “pedigree”. CNT differs from this approach in a number of important ways. CNT is much simpler and cheaper than retrofitting RFIDs in the pharma supply chain, or trying to maintain a continuous, complex history of the chain of custody for billions of drug packages. And unlike the FDA plan, it is strictly voluntary. CNT also invites consumer involvement, while under the FDA plan, consumers won't be able to participate because few will own RFID readers.

The CNT Bottle ID also differs significantly from the FDA's RFID “serialization code”. The Bottle ID is random, unpredictable, and non-sequential. It does not contain information about the product that can be used by counterfeiters to help guess valid numbers. Moreover, the CNT Bottle ID requires far fewer bytes (2-4) than the 12-byte minimum code envisioned by the FDA.^[6]

Another key difference between CNT and the FDA approach—or other schemes for tracking pedigree—is that counterfeiting hardware is of little value to an adversary under a CNT scheme. This is because the CNT Bottle ID is a token or virtual tag; its security and functionality does not depend on the specific mechanism used to record or encode it on the container or packaging. With non-CNT

approaches, in contrast, it is easy for an adversary to counterfeit drug packaging, bar codes, RFIDs^[17,18], or “certificates of authenticity”^[21,22]. Depending on details of the pedigree program, this allows him to partially, temporarily, or wholly hide his counterfeiting.

Additional Comments

Alternate Means of Calling In

Consumers might find it particularly easy to hold the bottle up to the phone, press a button on a microchip, and let the bottle “beep” its Lot Number and Bottle ID into the phone using standard telephone touch tone frequencies.^[23] Currently, micro-circuits on greeting cards can talk or sing; these cost under \$2 each in quantity (including the battery), and prices are certain to decrease over time.

CNT Costs

Nowadays, the cost for automated printing of individual numbers on the fly (even randomly chosen numbers) onto containers or adhesive labels is very low. Costs are also modest for maintaining a single automated CNT database, which could be implemented on a single personal computer. The costs of establishing and running a CNT web site should also be modest because the web site is little more than a big look-up table. Having a bank of automated, voice-recognition phone lines for CNT callers, on the other hand, would be more expensive. Probably the greatest cost associated with CNT would be in educating customers and the public, including consumers, pharmacists, and physicians about the CNT system and which URL or phone number to use.

Initially, the use of a CNT system might be limited to high-volume customers only. Pharmaceutical companies might also keep costs down by establishing a joint CNT system with other manufacturers, or by seeking government sponsorship.

It might also make sense not to routinely recommend that customers call in unless/until there is an independent evidence for widespread counterfeiting of a particular drug, and/or there is a public counterfeit scare that requires positive action.

CNT as a Service

If the Bottle IDs are printed in advance as adhesive labels or inserts, the entire CNT system could be run by a third party as a relatively small service business.

Bottle IDs would be (securely) provided to pharmaceutical manufacturers as needed. Responsibility for maintaining the CNT database and operating the web site and phone lines would rest with the service provider.

Additional Benefits

Asking customers—especially consumers—to take personal responsibility for checking the authenticity of their own medicines may have significant educational, behavioral, legal, and public health benefits. Fortunately, customers who aren't concerned about counterfeiting will not be bothered; they can just ignore the CNT system. CNT publicity campaigns probably need to emphasize to consumers what they have to gain by calling-in, but should also point out that their participation can help others.

For pharmaceutical companies, information provided by CNT callers can lead to a better understanding of customers and the market. Pharmaceutical companies might also benefit from enhanced public and government good will by taking proactive measures to deal with counterfeiting. Moreover, if CNT callers can be encouraged to mail in their counterfeit pharmaceuticals, we stand to learn more about the nature and extent of counterfeiting, and perhaps can more rapidly identify public health risks.

Conclusion

The “Call-in the Numeric Token” (CNT) technique is based on the idea of assigning a unique, unpredictable ID number (i.e., a virtual tag or token) to each pharmaceutical container made by a manufacturer. Customers are then encouraged to use a web site or phone line to check on the validity of the numeric (“virtual”) tag found on or in the pharmaceutical container(s) they possess. Invalid numeric tags can be spotted immediately. Furthermore, the pooling of information from callers helps to spot (and perhaps trace) ID numbers that have been illegally replicated by counterfeiters. Counterfeiters are hampered by the fact that guessing valid ID numbers isn't practical, replicating valid IDs may be detected by the call-in process, and obtaining large numbers of valid ones will be challenging.

CNT—while certainly not a silver bullet for stopping all counterfeiting of pharmaceuticals—does appear to offer (at least in principle) the potential for impeding counterfeiters at relatively modest cost. It does not require expensive,

high-tech devices that are vulnerable to simple attacks. Mostly familiar technologies like the Internet and the telephone are involved.

It is uncertain the degree to which pharma customers and consumers might voluntarily participate in a CNT system. In one sense, it doesn't really matter. If they aren't currently concerned enough about counterfeiting to widely participate, perhaps we should trust their judgment. The CNT system, however, can still be kept in place relatively painlessly should they suddenly change their minds as a result of a public counterfeiting scare. Moreover, whether it is widely used or not, implementing a CNT system would demonstrate good faith on the part of pharmaceutical manufacturers in attempting to deal with the counterfeiting threat.

Acknowledgments & Disclaimers

Anthony Garcia, Eddie Bitzer, Otis Peterson, Jon Warner, and Alicia Herrera offered useful suggestions and assistance. The views expressed in this paper are those of the author, and should not necessarily be ascribed to Los Alamos National Laboratory or the United States Department of Energy. As of July 2005, the author has never been an employee, paid consultant, or grant recipient for the pharmaceutical industry, has no such interactions pending, and has no personal financial interest in pharmaceutical manufacturing or countermeasures to drug counterfeiting.

References

1. Wertheimer AI, Chaney NM, and Santella T. Counterfeit pharmaceuticals: current status and future projections. *J Am Pharm Assoc (Wash DC)* 2003 Nov-Dec; 43 (6): 710-7
2. Rudolf PM and Berstein, BG. Counterfeit drugs. *New England Journal of Medicine* 2004 April 1; 350 (14): 1384-6
3. Cockburn R, Newton PN, Agyarko EK, Akunyili D, and White NJ. The global threat of counterfeit drugs: why industry and governments must communicate the dangers. Available from URL: http://www.pharmamanufacturing.com/Media/MediaManager/Akunyili_counterfeitdrugs.pdf [Accessed 2005 July 6]
4. World Health Organization. Substandard and counterfeit medicines. Available from URL: <http://www.who.int/mediacentre/factsheets/2003/fs275/en> [Accessed 2005 July 6]
5. Hopkins DM, Kontnik LT, and Turnage MT. Counterfeiting exposed: how to protect your brand and market share. New York: Wiley, 2003
6. United States Food and Drug Administration (FDA). Combating counterfeit drugs. 2004 February. Available from URL: http://www.fda.gov/oc/initiatives/counterfeit/report02_04.html [Accessed 2005 July 6]
7. Johnston, RG. Tamper detection for safeguards and treaty monitoring: fantasies, realities, and potentials. *Nonproliferation Review* 2001 Spring; 8 (1): 102-115
8. Johnston RG and Garcia ARE. An annotated taxonomy of tag and seal vulnerabilities. *Journal of Nuclear Materials Management* 2000 Spring; 229 (3): 23-30
9. Johnston, RG. Tamper-indicating seals for nuclear disarmament and hazardous waste management. *Science and Global Security* 2001; 9 (2): 93-112
10. Anderson RJ. Security engineering. New York: Wiley, 2001
11. Los Alamos National Laboratory. Vulnerability assessment team home page. Available from URL: <http://pearl1.lanl.gov/seals.default.htm> [Accessed 2005 July 6]

12. Johnston RG, Garcia ARE, and Pacheco AN. Efficacy of tamper-indicating devices. *Journal of Homeland Security* 2002, April 16. Available from URL: <http://www.homelandsecurity.org/journal/Articles/displayarticle.asp?article=50> [Accessed 2005 July 6]
13. Johnston RG and Garcia ARE. Analyzing vulnerability results for tags and tamper-indicating seals. *Proceedings of the U.S. Army Conference on Applied Statistics*; 2001 October 24-26; Santa Fe, NM. pp. 60-88
14. Karsten R. Tags tag counterfeits: as counterfeiting methods become increasingly sophisticated, more advanced technologies are needed to fight back. *Manufacturing Chemist* 2003 January 1; 73 (1): pp-p
15. Deisingh A. Counterfeit drugs. *Chemistry and Industry* 2004 March 15; 54 (6): 16-18
16. Kontnik, L. Counterfeits: the cost of combat. *Pharmaceutical Executive* 2003 November 1. Available from URL: <http://www.pharmexec.com/pharmexec/article/articleDetail.jsp?id=75674> [Accessed 2005 July 6]
17. Johnston, RG. The state of the art—an introduction to technology. *Proceedings of the National Cargo Security Council Conference on Security Technology*; 2004 July 18-20; Linthicum Heights, MD
18. Johnston, RG and Warner, JS. Don't swallow the snake oil: understanding the limitations and vulnerabilities of high technology. *Security Management* (in press).
19. Menezes AJ, van Oorshot PC, Vanstone SA. *Handbook of applied cryptography*. New York: CRC Press, 1997
20. Mirkovic J, Dietrich S, Dittrich D, et al. *Internet denial of service: attack and defense mechanisms*. New York: Prentice Hall, 2004
21. Google Answers. Autograph authenticity. Available from URL: <http://answers.google.com/answers/threadview?id=482665> [Accessed 2005 July 6]
22. Newsfactor. Microsoft sues over fake certificates. Available from URL: http://www.newsfactor.com/story.xhtml?story_title=Microsoft-Sues-over-Fake-

Certificates&story_id=28770 [Accessed 2005 July 6]

23. Elert, Glenn. Beats. The Physics Handbook: Beats. Available from URL: <http://hypertextbook.com/physics/waves/beats/> [Accessed 2005 July 6]

Table 1 - The number of unique Bottle IDs and bottles allowed per Lot for various Bottle ID formats. To avoid confusing letters with numeric digits, the letters O and I (and letter L if lower case letters are used) might be excluded—somewhat reducing the values in columns 2 and 3.

bottle ID format	no. of unique IDs	maximum no. of bottles per lot
6 digits (2.5 bytes)	1 million	1,000
7 digits (2.9 bytes)	10 million	10,000
3 letters + 3 digits (3.0 bytes)	17.6 million	17,576
4 letters + 3 digits (3.6 bytes)	457 million	456,976

Table 2 - Accuracy in telling the next caller that he has a counterfeit under the assumption that the same valid Bottle ID has already been called in multiple times, and that there exists 1 authentic bottle, and N counterfeit bottles, all with the same valid Bottle ID. This table shows that by the time counterfeiters have made more than just a few replicates of the same Bottle ID, we can have great confidence that any one of the bottles called in with that ID is a counterfeit.

no. of counterfeits made (N)	accuracy= $N/(N+1)$	error rate
2	67%	33%
10	91%	9%
100	99%	1%
1,000	99.9%	0.1%
10,000	99.99%	0.01%

Lot: 4ZB1026
Exp: 04/06
Bottle ID: KSD709

Figure 1 - An example of the printing applied to a pill bottle, packaging, or other pharmaceutical container under the CNT scheme. In this case, the Bottle ID consists of 3 letters (A-Z) and 3 numeric digits (0-9).




Figure 2 - Percentage of callers reporting the same (valid) Bottle ID who will be notified their drugs are counterfeit vs. the number of callers reporting that Bottle ID. This is plotted for 4 different thresholds (2, 3, 5, and 10 callers). The assumption for this graph is that counterfeiters have created a large number of counterfeits with the same (valid) Bottle ID number. Note that if earlier callers are re-contacted after the call-in threshold has been achieved for a given Bottle ID, then 100% of all callers will be informed they hold counterfeits rather than the percentage plotted here.